Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization

International Journal of Ophthalmology

Volumn 7, Issue 2, 2014, Pages 220-225

  Onder, Halil Ibrahim ^a   Erdurmus, Mesut ^b   Bucak, Yasin Yiicel ^c   Simavli, Hiiseyin ^c   Oktay, Murat ^a   Kukner, Ahmet Sahap ^b  

^a DUZCE UNIVERSITY   (Turkey)

^b ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

^c Izzet Baysal Hospital   (Turkey)

Author keywords

Corneal neovascularization; Regorafenib; Tyrosine kinase inhibitor

Indexed keywords

EID: 84899893095     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2014.02.06     Document Type: Article

References (34)

1. Chang JH, Garg NK, Lunde E, Han KY, Jain S,Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012;57(s):4l5-429. [PMCfree article] [PubMed]
2. Stevenson W, Cheng SF, Dastjerdi MH, Ferrari G, Dana R. Corneal neovascularization andthe utility of topical VEGF inhibition: ranibizumab (Lucentis) us bevacizumab (Avastin) Ocul Surf. 2012;10(2):67-83. [PMCfree article] [PubMed]
3. Peyman GA, Kivilcim M, Morales AM, DellaCroce JT, Con way MD. Inhibition of corneal anggenesis by ascorbic acid in the rat model. Graefes Arch Clin Exp Ophthalmol. 2007;245(10):l46l-l467. [PubMed]
4. Bachmann B, Tayr RS, Cursiefen C. The association between corneal neovascularization andvisual acuity: a systematic review. Acta Ophthalmol. 2013;9l(l):l2-l9. [PubMed]
5. MorabitoA, DeMa E, Di Ma M, Norm anno N, PerroneF. Tyrosinekinase inhibitors of vascular endoth el ial growth factor receptors in clinical trials: current status andfuture directions. Oncogist. 2006;ll(7):753-764. [PubMed]
6. Ellenberg D, Azar DT, Hallak JA, Tobaigy F, Han KY, Jain S, Zhou Z, Chang JH. Novel aspects of corneal anggenicand lymphanggenic privilege. Prog Retin Eye Res. 20l0;29(3):208-248. [PMCfree article] [PubMed]
7. Acidic/neutral amino acid residues substitution in NH2 terminal of plasminogen kringles exerts en ha need effects on corneal neovascularization. Cornea. 2013;32(5):68o-688. [PubMed]
8. Kvanta A, Sarman S, Fagerholm P, SeregardS, Steen B. Expressn of matrix metalroteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-Associated corneal neovascularization. Exp Eye Res. 20007O(4):4l9-428. [PubMed]
9. Zheng Y,Gu Q, Xu X. Inhibition of ocular neovascularization by a novel peptide derived from human placenta growth factor-l. Acta Ophthalmol. 2012;9o(7):e5l2-523. [PubMed]
10. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schiitz G, Thierauch KH, Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of anggenic, stromal andoncogenic receptor tyrosinekinases with potent preclinical a ntitum or activity. Int J Cancer. 20115129(1) :24s-255. [PubMed]
11. Eisen T, Joensuu H, Nathan PD, Harper PG, Wojtukiewicz MZ, Nicholson S, Bahl A, Tomczak P, Pyrhonen S, Fife K, Bono P, Boxall J, Wagner A, Jeffers M, Lin T, Quinn DI. Regorafenib for patients with prevusly untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol. 2012;l3(10):1055-1062. [PubMed]
12. l2.Totan Y, Ay din E, CekicO, Cihan Dagglu M, Borazan M, Daglglu K, GiiltekA. Effect of caffeic acid ph en ethyl ester on corneal neovascularization in rats. Curr Eye Res. 2001;23(4):29l-297. [PubMed]
13. 13-Burits M, Bucar F. Antixidant activity of Nigella sativa essential oil. Phytother Res. 2000514(5) 1323-328. [PubMed]
14. Lu P, Li L, Mukaida N, Zhang X. Alkali-induced corneal neovascularization is independent of CXCR2-mediated neutrophil infiltration. Cornea. 2007;26(2):l99-206. [PubMed]
15. PhilippW, Speicher L, Hum pel C. Expressn of vascular endoth el ial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;4l(9):25l4-2522. [PubMed]
16. Murata M, Shimizu S, Horiuchi S, Taira M. Inhibitory effect of triamcinoneacetonideon corneal neovascularization Graefes Arch Clin Exp Ophthalmol. 2006;244(2):205-209. [PubMed]
17. Gupta D, Illingworth C. Treatments for corneal neovascularization: a review. Cornea. 2011;3o(8):927-938. [PubMed]
18. Chung JH, Kang YG, Kim HJ. Effect of 0.1% dexamethasone on epithelial healing in experimental corneal alkali wounds: morphogical changes during the repair process. Graefes Arch Clin Exp Ophthalmol. 19985236(73:537-545. [PubMed]
19. Dan L, Shi-ng Y, Miao-li L, Yong-ping L, Hong-jie M, Ying Z, Xiang-gui W. Inhibitory effect of oral doxycyclineon neovascularization in a rat corneal alkali burn model of anggenesis. Curr Eye Res. 2008;33(8):653-66o. [PubMed]
20. Castro MR, Lutz D, Edelman JL. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal andchoroidal neovascularization. Exp Eye Res. 2004;79(2):275-285. [PubMed]
21. Peyman GA, Kazi AA, Riazi-Esfahani M, Ay din E, Kivilcim M, Sanders DR. The effect of combinations of flurbiprofen, 10w molecular weight heparin, and doxycyclineon theinhibition of corneal neovascularization. Cornea. 2006;25(5):582-585. [PubMed]
22. Erdurmus, M, Yagci R, Yilmaz B, Hepsen IF, Turkmen C, Ay din B, Karadag R. Inhibitory effects of topical thymoquinoneon corneal neovascularization. Cornea. 2007;26(6):715-719. [PubMed]
23. Sonmez B, Beden U, Erkan D. Regressn of severe corneal stromal neovascularization with topical cycsporine 0.05% after penetrating keratoplasty for fungal corneal ulcer. Int Ophthalmol. 2009;29(2):l23-l25. [PubMed]
24. Joussen AM, Kruse FE, Volcker HE, Kirchhof B. Topical application of methotrexate for inhibition of corneal anggenesis. Graefes Arch Clin Exp Ophthalmol. l999;237(ll):920-927. [PubMed]
25. Gerten G. Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea. 2008;27(10):ll95-ll99. [PubMed]
26. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 2007;l25(6):834-836. [PubMed]
27. Ferrara N. VEGF and the quest for tumour anggenesis factors. Nat Rev Cancer. 200252(10) :79s-803. [PubMed]
28. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245(10):l577-l579. [PubMed]
29. Mason JO, 3rd, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2006;l42(4):685-688. [PubMed]
30. Bock F, Konig Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008;246(2):28l-284. [PubMed]
31. Keskin U, Totan Y, Karadag R, Erdurmus M, Ay din B. Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization. Ophthalmic Res. 2012;47(l):l3-l8. [PubMed]
32. Zaki K, Aslam S, Eisen T. Regorafenib (BAY 73-4506): Stromal andOncogenic Multikinase Inhibitor with Potential Activity in Renal Cell Carcinoma. Curr Oncol Rep. 2013;ls(2):9l-97. [PubMed]
33. Li C, Li L, Cheng R, Dai Z, Li C, YaoY, Zhou T, Yang Z, GaoG, Yang X. Acidic/Neutral AminoAcid Residues Substitution in NH2 Terminal of Plasminogen Kringles Exerts Enhanced Effects on Corneal Neovascularization. Cornea. 2013;32(5):68o-688. [PubMed]
34. Dai C, Liu G, Li L, XiaoY, Zhang X, Lu P. ADP-ribosylation factor as a novel target for corneal neovascularization regressn. Mol Vis. 2012;l8(2):2947-295. [PMCfree article] [PubMed]